2005, Number 5
<< Back Next >>
Med Cutan Iber Lat Am 2005; 33 (5)
Benefits of the isotretinoin therapy for cystic severe acne in hyperandrogenic patients with polycystic ovary syndrome
Carvalho LA, Carvalho LA
Language: Portugués
References: 20
Page: 211-218
PDF size: 179.28 Kb.
ABSTRACT
This study had the objective of verify the benefits of isotretinoin for treating severe acne in women with hyperandrogenism caused by Polycystic
Ovary Syndrome (PCOS). Eleven patients showing cystic and nodular inflammatory acne was diagnosed as PCOS patients and started a 20 weeks
treatment with isotretinoin with a minimum dose of 0.75mg/kg/day until reaching the total dose of 120mg/kg at the end of the protocol. Eleven
patients started the protocol but only 10 of them finished the treatment cycle. Eight of them had as results of the treatment cure of the severe
inflammatory acne without any decrease of the others hyperandrogenics signs. Improvement of the psycho-social behavior was related by the
patients and verified by the physicians during the protocol period. The skin and behavioral benefits was kept after six months of the end of the
treatment. The study concluded that isotretinoin can be an excellent choice for treating the severe inflammatory acne in PCOS women.
REFERENCES
Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in Adolescent Girls with Polycystic Ovary Syndrome. Arch Pediatr Adolesc Med. 2002;156:556 - 60.
Lobo R, Carmina E, The Importance of Diagnosing the Polycystic Ovary Syndrome. Ann Intern Med. 2000;132:989-93.
Taylor AE, Insulin-Lowering Medications in Polycystic Ovary Syndrome. Obstet Gynecol Clin, 2000;27:583-95.
Baillargeon JP, Iuorno MJ, Nestler JE, et al. Insulin Sensitizers for Polycystic Ovary Syndrome. Clin Obstet Gynaecol, 2003;46: 325-40.
Meirelles RMR. Desvendando os Mistérios da Mulher (pelo Menos os Endócrinos) Arq Bras Endocrinol Metab, 2001;45:317-9.
Tartagni M, Schonauer LM, De Salvia MA, et al. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril, 2000;73:718-23.
Shaw JC. Hormonal therapy in Dermatology. Dermatol Clin, 2001;19:169-78. 8. Meisler JG. Toward Optimal Health: The Experts Discuss Facial Skin and Related Concerns in Women. J Women Health, 2003;12:533-9.
Bershad SV. The Modern Age of Acne Therapy: A Review of Current Treatment Options. Mount Sinai J Medicine, 2001;68: 279-86.
Faure M. Acné et hormones. Rev Prat, 2002;52:850 -3.
Tan JKL, Vasey K, Fung KY. Attitudes of female Patients regarding Oral Contraceptives for Acne Treatment. J Cutan Med Surg, 2001:471-74.
Seaman HE, Vries CS, Farmer RDT. Differences in the use of combined oral contraceptives amongst women with and without acne. Hum Reprod, 2003;18:515 -21.
Krowchuk DP. Treating Acne. Med Clin North Am – Adolescent medicine. 2000:8: 811-24.
Orfanos CE, Zopuboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology.Drugs 1997;53:358–88.
American Academy of Dermatology Consensus Conference on the Safe an Optimal Use of Isotretinoin: Sumary and recommendations. J Am Acad Dermatol 2004;50:900 -6.
De Leo V, La Marca A, Petraglia F. Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome. Endocr Rev, 2003;24:633–67.
Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol, 2002;147:717–25.
Azziz R. The Evaluation and Management of Hirsutism. Obstet Gynecol, 2003;101:995-1007.
Ferriman D, Gallwey JD. Clinical Assessment of body hair growth in women. J Clin Endocrinol Metabol, 1961;21:1440 -47.
Hunter MH, Carek PJ. Evaluation and Treatment of Women with Hirsutism Am Fam Phycisian, 2003;67:2565-72.
Ludwig E. Classification of the types of androgenetic alopecia occuring in the female sex. Br J Dermatol 1977,97:247-54.
Full text